Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

#data science Review Open access Oct 2026

Biweekly gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a systematic review

Pancreatic cancer is associated with high morbidity and mortality. Gemcitabine plus nab-paclitaxel (GA), along with FOLFIRINOX and NALIRIFOX, is a standard first-line treatment for advanced/metastatic pancreatic ductal adenocarcinoma (mPDAC). However, the standard GA schedule (days 1, 8, and 15 of a 28-day cycle)...

C. Hoyek, C. Eslinger, Angelo Pirozzi et al. · 0 citations
Review Sep 2026

Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer

ABSTRACT Introduction Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy in which activating KRAS mutations, present in more than 90% of tumors, constitute the principal oncogenic driver. Advances in structural biology have enabled the pharmacologic targeting of KRAS, a protein historically regarded as...

Joanna Kreidi, C. Hoyek, C. Eslinger et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.